Familiáris hiperkoleszterinémia: vizsgálatok itt: Kína
21 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
- Where
- Beijing, Guangzhou, Hangzhou, Shanghai
- Életkor
- 6 év to 17 év
- People
- 153 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07058077 · EU 2024-519068-42-00 - 3. fázisNot yet taking people in KínaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
- Where
- Beijing, Chifeng, Guangzhou, Ha’erbin, Hangzhou, Hefei, Liuzhou, Luoyang, Nanchang, Nanjing, Sanya, Shanghai, Shantou, Shiyan, Suining, Tangshan, Tianjin, Yueyang, Zhengzhou, Zigong
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07930507 - No phaseTaking peopleGuideline Oriented Approach To Lipid Lowering In Asia-Pacific
- Where
- Dalian
- Életkor
- 18 év and over
- People
- 2000 worldwide
- Run by
- Stephen Nicholls
See details and how to joinNCT05325034 - Korai 1. fázisTaking peopleNGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
- Where
- Xi'an
- Életkor
- 12 év to 55 év
- People
- 21
- Run by
- First Affiliated Hospital Xi'an Jiaotong University
See details and how to joinNCT06125847 - 2. fázisTaking peoplePhase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 18
- Run by
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07591298 - 3. fázisTaking peopleStudy to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
- Where
- Beijing
- Életkor
- 2 év to 11 év
- People
- 9 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06597006 - 3. fázisTaking peopleA Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 135
- Run by
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07465263 - 4. fázisNot yet taking people in KínaRucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 29
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07674368 - 2/3. fázisTaking peopleA Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
- Where
- Nanjing
- Életkor
- 18 év to 85 év
- People
- 126
- Run by
- Beijing Suncadia Pharmaceuticals Co., Ltd
See details and how to joinNCT07404553 - 2. fázisTaking peopleA Dose-exploration Study of EDP167 in HoFH
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 20
- Run by
- Eddingpharm (Zhuhai) Co., Ltd.
See details and how to joinNCT07489209 - No phaseTaking peopleChild-Parent Familial Hypercholesterolemia Screening
- Where
- Chongqing, Hefei, Qidong, Shanghai, Taiyuan, Ürümqi
- Életkor
- 1 év to 3 év
- People
- 15 000
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT04529967 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
- Where
- Beijing, Shanghai
- Életkor
- 6 év to 11 év
- People
- 60 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06597019 - 3. fázisNot yet taking people in KínaA Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 760
- Run by
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07421297 - Korai 1. fázisNot yet taking people in KínaEarly-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 24
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07353398 - 3. fázisNot yet taking people in KínaA Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 900
- Run by
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
See details and how to joinNCT07421284 - 2. fázisNot yet taking people in KínaEvaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
- Where
- Changsha
- Életkor
- 12 év and over
- People
- 55
- Run by
- Beijing Suncadia Pharmaceuticals Co., Ltd
See details and how to joinNCT07133815 - 1. fázisNot yet taking people in KínaPharmacokinetics and Pharmacodynamics Study
- Where
- Qingdao
- Életkor
- 18 év to 65 év
- People
- 48
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07074236 - Korai 1. fázisTaking peopleClinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- RenJi Hospital
See details and how to joinNCT06458010 - 1. fázisCsak meghívásosA Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
- Where
- Chengdu
- Életkor
- 18 év to 55 év
- People
- 30
- Run by
- Hasten Biopharmaceutical Co., Ltd.
See details and how to joinNCT06504043 - 3. fázisTaking peopleA Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
- Where
- Beijing, Binzhou, Changsha, Chengdu, Daqing, Guangzhou, Heze, Jinan, Nanchang, Shijiazhuang, Tianjin, Wenzhou, Zibo
- Életkor
- 18 év and over
- People
- 210
- Run by
- Hasten Biopharmaceutical Co., Ltd.
See details and how to joinNCT06568471 - 1. fázisNot yet taking people in KínaExosome-based Nanoplatform for Ldlr mRNA Delivery in FH
- Where
- Xi'an
- Életkor
- 18 év to 45 év
- People
- 30
- Run by
- Tang-Du Hospital
See details and how to joinNCT05043181